Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile
Kathryn Gallaway, MD

@ke_gallaway

34 y/o G2P2 presents w/ insatiable thirst for knowledge of unknown etiology | Philosophy @RiceUniversity | MD @UTSWNews | Associate Medical Director @DAVAOnc

ID: 1558842292605259777

linkhttps://www.linkedin.com/in/kathryn-gallaway-845136236/ calendar_today14-08-2022 15:46:19

958 Tweet

383 Followers

917 Following

Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Dr. Neil Kay Mayo Clinic discusses MRD in CLL, highlighting a few pearls to consider 🩸 Blood can be used, with high concordance to BM (less so in CD20 regimens) 🧮 10^-4 sufficient 🩺 uMRD at EOT can guide PFS discussions, may not help guide treatment decisions at this time

Dr. Neil Kay <a href="/MayoClinic/">Mayo Clinic</a> discusses MRD in CLL, highlighting a few pearls to consider

🩸 Blood can be used, with high concordance to BM (less so in CD20 regimens)
🧮 10^-4 sufficient
🩺 uMRD at EOT can guide PFS discussions, may not help guide treatment decisions at this time
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Phenomenal work from Mark Roschewski diving into the biology and treatment strategies of immune privileged LBCL ashpublications.org/blood/article-… Looking forward to updated data from trials considering response adapted chemo after ibrutinib a window study for acalabrutinib

Phenomenal work from <a href="/RoschewskiMD/">Mark Roschewski</a> diving into the biology and treatment strategies of immune privileged LBCL

ashpublications.org/blood/article-…

Looking forward to updated data from trials considering response adapted chemo after ibrutinib a window study for acalabrutinib
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Energizing talk from Dr. Jeremy Abramson breaking down pros and cons of Pola-R-CHP The essential points of this talk apply to any new cancer therapy providing benefit over SOC (e.g. improved PFS, lower toxicity, etc) WITHOUT improved OS Quality of OS counts!!

Energizing talk from Dr. Jeremy Abramson breaking down pros and cons of Pola-R-CHP

The essential points of this talk apply to any new cancer therapy providing benefit over SOC (e.g. improved PFS, lower toxicity, etc) WITHOUT improved OS

Quality of OS counts!!
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Dr. David Miklos Stanford BMT & Cell Therapy kicks of Saturday at #DAVAHeme with intriguing update on secondary malignancy post-CD19 CAR nejm.org/doi/full/10.10… In this patient, the secondary TCL cells were present prior to CAR infusion. Novel mechanism for secondary malignancy post-CAR?

Dr. David Miklos <a href="/StanfordBMT_CT/">Stanford BMT & Cell Therapy</a> kicks of Saturday at #DAVAHeme with intriguing update on secondary malignancy post-CD19 CAR

nejm.org/doi/full/10.10…

In this patient, the secondary TCL cells were present prior to CAR infusion. Novel mechanism for secondary malignancy post-CAR?
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Dr. Doris Hansen Moffitt Cancer Center discusses CAR-T moving to earlier LOT in MM, necessitating more refined patient selection tools MyCARe is the first model to predict outcome to CAR based on: 🦴EMD/PCL 🧬High-risk cytogenetics 🩸Ferritin 💊LEN response ncbi.nlm.nih.gov/pmc/articles/P…

Dr. Doris Hansen <a href="/MoffittNews/">Moffitt Cancer Center</a> discusses CAR-T moving to earlier LOT in MM, necessitating more refined patient selection tools

MyCARe is the first model to predict outcome to CAR based on:
🦴EMD/PCL
🧬High-risk cytogenetics
🩸Ferritin
💊LEN response

ncbi.nlm.nih.gov/pmc/articles/P…
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

With BCMA CAR/BsAbs moving to earlier lines, new post-BCMA strategies are essential Bhagirath Dholaria, MD shares early phase 1 data for P-BCMA-ALLO1, an off the shelf CAR with deep responses and high response rate after prior BCMA Expanded data coming at IMS Myeloma Society next month!

With BCMA CAR/BsAbs moving to earlier lines, new post-BCMA strategies are essential

<a href="/DholariaMD/">Bhagirath Dholaria, MD</a> shares early phase 1 data for P-BCMA-ALLO1, an off the shelf CAR with deep responses and high response rate after prior BCMA

Expanded data coming at IMS <a href="/Myeloma_Society/">Myeloma Society</a> next month!
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Another novel BCMA allo-CAR-T presented by Adriana Rossi with an immune cloaking technology to reduce rejection The phase 1 CaMMouflage trial is currently enrolling! clinicaltrials.gov/study/NCT05722…

Another novel BCMA allo-CAR-T presented by <a href="/Dr_AdrianaRossi/">Adriana Rossi</a> with an immune cloaking technology to reduce rejection

The phase 1 CaMMouflage trial is currently enrolling!
clinicaltrials.gov/study/NCT05722…
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Dr. Jennifer Lue @MSKCC shares rationale for targeting BCL6. BCL6 modulates DNA repair facilitating germinal center affinity maturation and is aberrantly expressed in some FL/DLBCL Two BCL6 degraders are currently in development: clinicaltrials.gov/study/NCT06090… clinicaltrials.gov/study/NCT06393…

Dr. Jennifer Lue @MSKCC shares rationale for targeting BCL6.

BCL6 modulates DNA repair facilitating germinal center affinity maturation and is aberrantly expressed in some FL/DLBCL

Two BCL6 degraders are currently in development:
clinicaltrials.gov/study/NCT06090…
clinicaltrials.gov/study/NCT06393…
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Dr. Shannon Maude Children's Hospital shares data on CD19 CAR reinfusion for pediatric ALL patients with early B cell recovery Reinfusion resulted in 50% response rate with very low rates of CRS or neurotoxicity, may reduce relapse risk, but more data needed ashpublications.org/bloodadvances/…

Dr. Shannon Maude <a href="/ChildrensPhila/">Children's Hospital</a> shares data on CD19 CAR reinfusion for pediatric ALL patients with early B cell recovery

Reinfusion resulted in 50% response rate with very low rates of CRS or neurotoxicity, may reduce relapse risk, but more data needed

ashpublications.org/bloodadvances/…
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Dr. Vinod Pullarkat City of Hope shares pros/cons of CART as consolidation for B-ALL. ✅Easier logistics vs ASCT ✅Less toxic with low disease burden ❌Long term outcome w/o ASCT unclear ❌Cost, access Early data for NCT05707273 encouraging. Looking forward to update at #ASH2024

Dr. Vinod Pullarkat <a href="/cityofhope/">City of Hope</a> shares pros/cons of CART as consolidation for B-ALL.

✅Easier logistics vs ASCT
✅Less toxic with low disease burden
❌Long term outcome w/o ASCT unclear
❌Cost, access

Early data for NCT05707273 encouraging. Looking forward to update at #ASH2024
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Dr. Robert Hasserjian Mass General Cancer Center kicks off MDS session w/ tour de force MDS classification lecture ➖Genetically-defined MDS classification can inform therapy ➖Blasts strongly prognostic, but likely reflect stage rather than subtype Need 6th edition WHO classification‼️

Dr. Robert Hasserjian <a href="/MGHCancerCenter/">Mass General Cancer Center</a> kicks off MDS session w/ tour de force MDS classification lecture

➖Genetically-defined MDS classification can inform therapy
➖Blasts strongly prognostic, but likely reflect stage rather than subtype

Need 6th edition WHO classification‼️
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Exciting early results for synergistic combination of IRAK4i and BTKi in PCNSL presented by Christopher D'Angelo in our uncommon lymphoma session Expansion cohort for TakeAim Lymphoma trial is currently enrolling! clinicaltrials.gov/study/NCT03328…

Exciting early results for synergistic combination of IRAK4i and BTKi in PCNSL presented by <a href="/crdangelo9/">Christopher D'Angelo</a> in our uncommon lymphoma session

Expansion cohort for TakeAim Lymphoma trial is currently enrolling!
clinicaltrials.gov/study/NCT03328…
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

The prognosis for DHL and BL patients with R/R disease is abysmal. Ariela Noy builds case for 1L bispecifics + chemo Fantastic Data and ongoing trial for Epco + RCHOP: ncbi.nlm.nih.gov/pmc/articles/P… clinicaltrials.gov/study/NCT05578… MSK Oncology Updates proposed trial for Epco + REPOCH

The prognosis for DHL and BL patients with R/R disease is abysmal. <a href="/ArielaNoyMD/">Ariela Noy</a> builds case for 1L bispecifics + chemo

Fantastic Data and ongoing trial for Epco + RCHOP:
ncbi.nlm.nih.gov/pmc/articles/P…
clinicaltrials.gov/study/NCT05578…

<a href="/MSKCC_OncoNotes/">MSK Oncology Updates</a> proposed trial for Epco + REPOCH
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Could myeloma ✨be✨ any more crowded? Joshua Richter, MD, FACP kicks off final day of #DAVAHeme w/ nice review of DREAMM-7/DREAMM-8 which may bring blenrep back for another round 🏡Easily administered in community ⬇️CRS, ICANS, Infxn 💉Q4W-Q12W dosing Where do we squeeze it in?

Could myeloma ✨be✨ any more crowded?

<a href="/JoshuaRichterMD/">Joshua Richter, MD, FACP</a> kicks off final day of #DAVAHeme w/ nice review of DREAMM-7/DREAMM-8 which may bring blenrep back for another round

🏡Easily administered in community
⬇️CRS, ICANS, Infxn
💉Q4W-Q12W dosing

Where do we squeeze it in?
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Fascinating work being done with James Blachly in the rapidly emerging field of hereditary hematologic malignancies 🦓 Check out these referral indications to determine if your patient and their family may benefit from a HALT referral The James

Fascinating work being done with <a href="/jamesblachly/">James Blachly</a> in the rapidly emerging field of hereditary hematologic malignancies 🦓

Check out these referral indications to determine if your patient and their family may benefit from a HALT referral <a href="/OSUCCC_James/">The James</a>
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Dr. Aaron Goldberg Memorial Sloan Kettering Cancer Center discusses single-cell MRD which is more sensitive and more descriptive of the clonal architecture of residual AML science.org/doi/10.1126/sc… Clinical trial to control MRD-positive AML is planned! clinicaltrials.gov/study/NCT06284…

Dr. Aaron Goldberg <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a> discusses single-cell MRD which is more sensitive and more descriptive of the clonal architecture of residual AML

science.org/doi/10.1126/sc…

Clinical trial to control MRD-positive AML is planned!

clinicaltrials.gov/study/NCT06284…
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Great talk from Dr. Denis Slaymon UCLA Health sharing the preclinical data supporting a chemo-free combination of tucatinib, trastuzumab, and ribociclib in HER2+ breast cancer. 📣Phase Ib/II trial currently enrolling: clinicaltrials.gov/study/NCT05319… #DAVABreast

Great talk from Dr. Denis Slaymon <a href="/UCLAHealth/">UCLA Health</a> sharing the preclinical data supporting a chemo-free combination of tucatinib, trastuzumab, and ribociclib in HER2+ breast cancer.

📣Phase Ib/II trial currently enrolling: clinicaltrials.gov/study/NCT05319…

#DAVABreast
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Great work at Siteman Cancer Center and Fred & Pamela Buffett Cancer Center presented by Jairam Krishnamurthy and Dr. Nusayba Bagegni demonstrating that incomplete TKa suppression at C1D15 may identify pts with CDK 4/6i resistant tumors Two trials with DiviTum ongoing: clinicaltrials.gov/study/NCT04968… clinicaltrials.gov/study/NCT05977…

Great work at <a href="/SitemanCenter/">Siteman Cancer Center</a> and <a href="/BuffettCancer/">Fred & Pamela Buffett Cancer Center</a> presented by <a href="/DrJairamK/">Jairam Krishnamurthy</a> and Dr. Nusayba Bagegni demonstrating that incomplete TKa suppression at C1D15 may identify pts with CDK 4/6i resistant tumors

Two trials with DiviTum ongoing:
clinicaltrials.gov/study/NCT04968…
clinicaltrials.gov/study/NCT05977…
Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

ADC resistance and sequencing is something of a black box, but Dr. Ana Garrido-Castro Dana-Farber’s Breast Oncology Center shares upcoming trial TRADE-DXd which aims to shed light on key unanswered questions Is there a preferred initial ADC? Who can benefit from sequencing? clinicaltrials.gov/study/NCT06533…

Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo

Exciting to see so many options emerging for germline BRCA1/2 mutation patients! 👏 judy garber shares multiple ongoing trials with targeted therapies and tumor vaccines that may one day expand options beyond prophylactic surgery or allow surgery to be deferred #DAVABreast

Exciting to see so many options emerging for germline BRCA1/2 mutation patients! 👏

<a href="/judygarber5/">judy garber</a> shares multiple ongoing trials with targeted therapies and tumor vaccines that may one day expand options beyond prophylactic surgery or allow surgery to be deferred

#DAVABreast